Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 12/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10752506 | 0.85 | SPHK2 (0.50) | SPHK2SPHK1 | |
| SCHEMBL14836855 | 0.83 | MMEL1 (0.52) | SPHK1ALDH1A1MAPK1L3MBTL1NPC1 | |
| SCHEMBL28152602 | 0.83 | ALDH1A1 (0.46) | SPHK1ALDH1A1MAPK1L3MBTL1NPC1 | |
| SCHEMBL19656275 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1NPC1RAB9A | |
| SCHEMBL21161788 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1NPC1RAB9A | |
| SCHEMBL20333005 | 0.81 | ALDH1A1 (0.50) | SPHK2ALDH1A1MAPK1L3MBTL1NPC1 | |
| SCHEMBL24705627 | 0.81 | SPHK1 (0.50) | SPHK1ALDH1A1MAPK1L3MBTL1NPC1 | |
| SCHEMBL20966402 | 0.81 | SPHK1 (0.58) | SPHK2SPHK1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL18626013 | 0.81 | SPHK1 (0.50) | SPHK1ALDH1A1MAPK1L3MBTL1NPC1 | |
| SCHEMBL2430773 | 0.81 | CHRNB2 (0.53) | SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | SPHK2 2209/4885SPHK1 1799/4885ALDH1A1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.